Video: Dr. Matthew Cooperberg on Surgery for Aggressive Prostate Cancer

“Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the rise in aggressive management of men with high-risk prostate cancer. Cooperberg says the proportion of men who are receiving hormonal therapy alone had been rising consistently over the course of a 15 year period, up until 2010, to about 50%. Since then, Cooperberg says that number has dropped to about half of what it was, or 25%, which is attributed to more aggressive treatment.

“Cooperberg says local therapy for men with high-risk prostate cancer was normally radiotherapy, with surgery not being nearly as common. He adds that a growing body of evidence dictates that surgery in prostate cancer may be a more effective local therapy than radiation alone. According to the body of evidence, cancer-related survival and overall survival were normally boosted when surgery was involved for these patients.”

Click through to watch the video.


Local Tumor Removal Followed by TKI Treatment May Be Effective in Lung Cancer Patients Resistant to TKIs

Many non-small cell lung cancer (NSCLC) patients who receive EGFR-tyrosine kinase inhibitors (TKIs) like erlotinib (Tarceva) and gefitinib (Iressa) develop drug resistance. Some of these patients may also have a small number of metastases (oligometastatic disease), which can be destroyed with local therapy. Local therapy methods include surgical removal, radiation, or electrical current produced by high-frequency radio waves (radiofrequency ablation). A recent study explored the use of local therapy, followed by renewed treatment with EGFR-TKIs, in patients with oligometastatic NSCLC who had become resistant to EGFR-TKIs. The treatment was well tolerated and effective, especially for patients in whom local therapy had removed all known tumors.

Research paper: http://journals.lww.com/jto/Abstract/2013/03000/Local_Therapy_with_Continued_EGFR_Tyrosine_Kinase.14.aspx